# Satellos Bioscience Inc. (MSLE)

> Source: Nexqual · https://nexqual.com/MSLE · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Satellos Bioscience Inc. (MSLE), nexqual.com/MSLE" · informational, not investment advice.

**Price:** USD 6.84 (+3.17% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 6.63 · day 6.52–7.06 · 52w 5.3–13.4 · market cap $145M · NGM

## Key facts
- Analysts: Buy (mean 1.86 on a 1–5 scale) (7 analysts), mean target USD 24.17 (range 16–40).
- Total return with dividends: 1Y +0.0% vs S&P 500 +18.1%; 5Y -54.2% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -0.63, revenue estimate $0K.

## Analysts
Consensus Buy (mean 1.86 on a 1–5 scale), 7 analysts; mean target USD 24.17 (low 16, high 40).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-08 | Craig-Hallum | Initiated | Buy | $24 |
| 2026-08-17 | HC Wainwright & Co. | Reiterated | Buy | $18 |
| 2026-07-09 | HC Wainwright & Co. | Target raised | Buy | $11 → $18 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | +0.0% | -54.2% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +0.0% | -14.4% |
| Volatility (annualized) | 81.5% | 199.5% |
| Max drawdown | -57.0% (Mar 2026→Apr 2026) | -97.6% (Oct 2021→Aug 2022) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/MSLE · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt